Safety Evaluation of Prismocitrate 18 in Patients Receiving CRRT
Status:
Not yet recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
Prismocitrate 18 is a continuous renal replacement therapy (CRRT) solution to be used as a
renal replacement solution and as an anticoagulant to prevent blood clotting in the
extracorporeal circuit. The objective of this study is to confirm the safety of Prismocitrate
18 in patients receiving CRRT using continuous venovenous hemodiafiltration (CVVHDF) or
continuous venovenous hemofiltration (CVVH). The study period of the patient's CRRT will be
up to 10 days.